Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Antiand#195;and#162;and#194;and#8364;and#194;and#8220;Interleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer
median progression-free survival was 1.8 months (95% confidence interval, 0.8-3.6). Overall and progression-free survival tended to be longer in patients with modest than in patients with higher ... treatment that does…

